News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
ImmunoGen, Inc. Announces Sanofi-Aventis (France) Licenses Expanded Access to the Company’s TAP Technology
August 13, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that sanofi-aventis has exercised its option under a 2006 agreement for expanded access to ImmunoGen’s Tumor-Activated Prodrug (TAP) technology.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Sanofi
MORE ON THIS TOPIC
Podcast
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
March 11, 2026
·
1 min read
·
Heather McKenzie
C-suite
BioNTech Founders To Leave Famed mRNA Biotech for New Venture
March 10, 2026
·
2 min read
·
Annalee Armstrong
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
March 10, 2026
·
3 min read
·
Nick Paul Taylor
Funding
AI-Focused Fund Breakout Raises $114M To Support Early-Stage Biotechs
March 10, 2026
·
2 min read
·
Tristan Manalac
